WO2021073249A1 - UTILISATION DE β-NMN DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT OU LA PRÉVENTION DE LÉSIONS D'ORGANE INDUITES PAR UNE SEPTICÉMIE - Google Patents

UTILISATION DE β-NMN DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT OU LA PRÉVENTION DE LÉSIONS D'ORGANE INDUITES PAR UNE SEPTICÉMIE Download PDF

Info

Publication number
WO2021073249A1
WO2021073249A1 PCT/CN2020/110120 CN2020110120W WO2021073249A1 WO 2021073249 A1 WO2021073249 A1 WO 2021073249A1 CN 2020110120 W CN2020110120 W CN 2020110120W WO 2021073249 A1 WO2021073249 A1 WO 2021073249A1
Authority
WO
WIPO (PCT)
Prior art keywords
sepsis
mice
nicotinamide mononucleotide
damage
tissue
Prior art date
Application number
PCT/CN2020/110120
Other languages
English (en)
Chinese (zh)
Inventor
彭天庆
曹婷
郑东
李会丽
Original Assignee
苏州大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州大学 filed Critical 苏州大学
Publication of WO2021073249A1 publication Critical patent/WO2021073249A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to the field of biomedicine, in particular to the application of ⁇ -NMN in the preparation of a medicine for the treatment and prevention of septic organ damage.
  • Sepsis is a life-threatening multiple organ dysfunction caused by the imbalance of the body response after infection, which can develop into septic shock and multiple organ dysfunction syndrome (MODS), which is clinical One of the leading causes of death in critically ill patients.
  • MODS multiple organ dysfunction syndrome
  • the research data of domestic and foreign scholars shows that despite the continuous progress of "clustered" treatment strategies such as capacity assessment and resuscitation, early anti-infection and organ support, the mortality rate of patients remains high. So far, there are no effective measures to prevent and treat sepsis. Therefore, it is urgent to find new targets and new treatment measures for the prevention and treatment of sepsis.
  • Fluid resuscitation Most patients with sepsis will have circulatory failure in the early stage. It is determined that patients with sepsis have persistent hypotension. Before being admitted to the intensive care unit, the initial resuscitation and volume expansion treatment will be carried out through intravenous rehydration. However, in patients with sepsis, the diastolic function of the heart is limited, and a large amount of crystalloid infusion within a short period of time may exceed the compensatory capacity of the patient’s heart. This will not only not increase cardiac output, but will cause pulmonary edema and high center. Serious hemodynamic consequences including liver and kidney damage caused by venous pressure. Therefore, this also puts forward higher requirements for clinicians in the evaluation of fluid type, measurement, and course of treatment.
  • vasoactive drugs In order to make the patient's average arterial pressure greater than or equal to 65mmHg, vasopressor drugs are needed. Generally, norepinephrine is the first choice, and vasopressin can be used to increase the average arterial pressure value. However, the actual application, dosage and choice of drugs for patients with septic shock are also controversial. In addition to norepinephrine and vasopressin, angiotensin II has gradually become more prominent in the role of vasoactive drugs. Studies have found that angiotensin II can effectively increase the arteries of patients with vasodilatory shock whose conventional vasoactive drugs are ineffective. blood pressure. As for the timing of the application of vasoactive drugs and the appropriate reduction or even discontinuation, there is still no unified conclusion.
  • vasoactive drugs and anti-infective drugs have always been the core strategy of the campaign to save sepsis, but there is a lack of specific treatment measures. Therefore, it is particularly urgent to continue pre-clinical basic research to provide effective and specific prevention and treatment programs.
  • Nicotinamide Mononucleotide is a nucleotide derived from ribose and nicotinamide. It can be synthesized in the body through two pathways: one is catalyzed by nicotinamide via nicotinamide phosphoribosyl transferase (NAMPT) Synthesis; the other way is by Nicotinamide riboside (Nicotinamide riboside) catalyzed synthesis by nicotinamide riboside kinase.
  • NAMPT nicotinamide phosphoribosyl transferase
  • ⁇ -Nicotinamide Mononucleotide ( ⁇ -Nicotinamide Mononucleotide, ⁇ -NMN) is the active form of nicotinamide mononucleotide, which acts as Nicotinamide adenine dinucleotide (NAD + ; also known as coenzyme)
  • NAD + is a coenzyme that transfers protons. It is an indispensable coenzyme in glycolysis, gluconeogenesis, tricarboxylic acid cycle, and respiratory chain. It plays an important role in providing energy to cells, repairing DNA, and anti-aging. The role of substitution.
  • NAD + Nicotinamide nucleotide adenylytransferase 1-3
  • NAD + accounts for 85% of the total body's NAD + and is the most important way to maintain the NAD+ content in the body.
  • studies have reported that the NAD + content in the body significantly decreases under sepsis conditions, and it may be closely related to the continued deterioration of the main organs in sepsis.
  • the purpose of the present invention is to provide an application of ⁇ -NMN in the preparation of drugs for the treatment and prevention of septic organ damage.
  • the present invention discloses a new type of treatment and/or prevention of septic organ damage. medicine.
  • the invention discloses the application of ⁇ -nicotinamide mononucleotide ( ⁇ -NMN) in the preparation of medicines for the treatment and/or prevention of organ damage caused by sepsis.
  • ⁇ -NMN ⁇ -nicotinamide mononucleotide
  • organ damage includes one or more of heart damage, lung damage, liver damage, and kidney damage.
  • the drug is administered by injection or oral administration.
  • injection administration includes intravenous and/or intraperitoneal injection administration.
  • the administration dose of the drug is 300-1000 mg/kg.
  • the dosage of the drug is 500 mg/kg.
  • the medicine is used to increase the reduction of coenzyme I (NAD + ) content caused by sepsis.
  • the medicine is used to reduce the activity of myeloperoxidase and the content of active oxygen and malondialdehyde in organs caused by sepsis.
  • the present invention has at least the following advantages:
  • the present invention discloses the new use of ⁇ -nicotinamide mononucleotide, which has therapeutic, preventive and protective effects on multiple organ damage caused by sepsis, thereby providing new treatment methods and approaches for diseases in related fields.
  • a single administration of ⁇ -nicotinamide mononucleotide can increase the level of NAD + in the body, improve the heart function of septic mice, and reduce the level of oxidative stress in sepsis mice. Reduce the damage of heart, liver, lung, kidney and other organs.
  • ⁇ -nicotinamide mononucleotide is simple: ⁇ -nicotinamide mononucleotide is easy to dissolve in water, no other special solvents are required, and it is very popular and maneuverable.
  • the route of administration can be diversified: In the present invention, both intravenous injection and intraperitoneal injection are effective. In addition, it can also be administered orally.
  • Figure 1 is the detection result of heart function, oxidative stress and inflammatory response in Example 2 of the present invention
  • Figure 2 is the detection results of lung histopathology, oxidative stress, inflammatory response and cell apoptosis in Example 2 of the present invention
  • Fig. 3 is the detection result of oxidative stress, cell damage and inflammatory reaction of liver tissue in Example 2 of the present invention
  • Figure 4 is the detection results of oxidative stress, cell damage and inflammatory reaction in kidney tissue in Example 2 of the present invention.
  • Figure 5 is the detection results of heart function, oxidative stress and inflammatory response in Example 3 of the present invention.
  • Figure 6 is the detection results of lung tissue oxidative stress, inflammatory response and cell apoptosis in Example 3 of the present invention.
  • Fig. 7 is the detection result of oxidative stress, cell damage and inflammatory reaction of liver tissue in Example 3 of the present invention.
  • Fig. 8 shows the detection results of oxidative stress, cell damage and inflammatory reaction in kidney tissue in Example 3 of the present invention.
  • the present invention mainly uses the following experimental methods to detect representative biochemical parameters and damage indicators of multiple organs in septic mice, which are briefly described as follows:
  • Serological testing Collect mouse peripheral serum, and use commercial kits to detect alanine aminotransferase (Alamine aminotransferase, also known as GPT) and aspartate aminotransferase (AST also known as GOT) that reflect liver function indicators; reaction Creatinine (Cr) and blood urea nitrogen (BUN), which are indicators of renal function.
  • GPT alanine aminotransferase
  • AST aspartate aminotransferase
  • BUN blood urea nitrogen
  • tissue reactive oxygen species Grind mouse heart, lung, liver and kidney tissues, add horseradish peroxidase and Amplex Red to detect the amount of reactive oxygen species produced in each tissue.
  • the final form of reactive oxygen species in tissue cells is hydrogen peroxide.
  • the product of hydrogen peroxide catalyzed by horseradish peroxidase can be labeled with a fluorescent signal carried by Amplex Red.
  • the strength of the fluorescence signal represents the production of reactive oxygen species in the tissue.
  • MDA Malondialdehyde
  • TBA Thiobarbituric acid
  • MDA is a natural product produced by organisms after lipid oxidation. When the cells of the body undergo oxidative stress, lipid oxidation also occurs. Some fatty acids will be decomposed into a series of complex compounds after oxidation, including MDA. The level of lipid oxidation in the body can be reflected by detecting the content of MDA, so the measurement of MDA is widely used as an indicator of lipid oxidation.
  • MDA can react with TBA to form a red MDA-TBA adduct. The latter has a maximum absorption at 535nm, so it can be detected by colorimetry.
  • TBA Thiobarbituric acid
  • Detection of protein carbonyl groups during oxidative stress, the effects of free radicals on proteins include protein peptide chain scission, cross-linking and polymerization between protein molecules, oxidative deamination of protein amino acids, and free radicals attacking protein reducing groups, The malondialdehyde produced by oxidative cleavage of lipids is cross-linked with molecules produced by amino groups on proteins.
  • protein oxidative damage there are two main detection indicators for protein oxidative damage, namely protein carbonyl production and nitrotyrosine production.
  • the protein carbonyl detection kit of Sigma-Aldrich is used to form a stable dinitrophenylhydrazine complex by the interaction between the protein carbonyl and 2,4-dinitrophenylhydrazine (DNPH), the latter can be detected at 375nm Maximum light absorption.
  • DNPH 2,4-dinitrophenylhydrazine
  • the commonly used detection methods for cell apoptosis mainly include: caspas-3 activity determination, caspase-3 cleavage fragment determination and TUNEL in situ staining. Among them, caspase-3 activity determination and TUNEL in situ staining are performed using commercial kits, and caspase-3 cleavage fragments are detected by western blot using related antibodies.
  • Evans blue staining method is mainly used in the present invention to evaluate the permeability of pulmonary capillary vessels. 30 minutes before euthanasia, the mice were injected with 0.4% Evans Blue solution (50 mg/kg) through the tail vein. After lavage with 10 ml of normal saline, the mouse lung tissue was weighed and homogenized with normal saline. Mix the tissue lysate with 2ml of formamide, incubate at 60°C for 16 hours and then centrifuge at 20000g at 4°C for 5 minutes. Aspirate the supernatant to determine the concentration of Evans Blue by spectrophotometry (620, 740nm), and evaluate the permeability of the capillaries by the leakage rate of Evans Blue in the lung tissue.
  • Myeloperoxidase is a heme protease containing heme prosthetic group secreted by neutrophils, monocytes and macrophages in certain tissues. It is a member of the heme peroxidase superfamily. Myeloperoxidase is a function and activation mark of neutrophils, and its level and activity changes represent the function and activity status of neutrophil polymorphonuclear leukocytes.
  • a commercial kit is used to reflect the level of enzyme activity by detecting the content of the myeloperoxidase catalytic substrate.
  • Hematoxylin-Eosin (HE) staining method is mainly used for pathological analysis of mouse lung tissue. After the mice were euthanized, the right lobe of the lung was collected, and an appropriate volume of 10% formalin tissue fixative was added. After being allowed to stand at room temperature for 24 hours, it was dehydrated by alcohol and embedded in paraffin. A paraffin section with a thickness of 0.5 mm was cut with a paraffin microtome, and hematoxylin-eosin staining was performed through deparaffinization, hydration, nuclear and cytoplasmic staining, and decolorization, and then the pathological changes of lung tissue structure were observed under a microscope.
  • HE Hematoxylin-Eosin
  • mice 7-8 weeks old C57 male mice (body weight around 25 grams) are placed in the animal turnover room for later use. Randomly select several mice as fecal donor mice for future use. Then the remaining mice were randomly divided into four groups: the control group, the control group plus ⁇ -nicotinamide mononucleotide group, the implanted stool group and the implanted stool plus ⁇ -nicotinamide mononucleotide group (the number of each group was greater than 5). only).
  • Implant feces to prepare a sepsis model take out the prepared fecal suspension, and implant feces into the abdominal cavity of experimental mice by intraperitoneal injection at a ratio of 50 ml/kg body weight. Subsequently, 1 ml of normal saline containing 4 micrograms of buprenorphine was subcutaneously injected into the mice to replenish electrolytes and relieve pain in the mice. The end of the experiment was 6 hours later, and the damage of the heart, liver, and kidney of mice in different experimental groups was analyzed.
  • the control group and the control group plus ⁇ -nicotinamide mononucleotide group did not undergo any operation, the stool implantation group and the stool implantation plus ⁇ -nicotinamide mononucleotide group were first prepared according to the above method to prepare the sepsis model.
  • Example 2 ⁇ -nicotinamide mononucleotide prevents multiple organ damage in septic mice
  • the administration method of intraperitoneal injection is adopted, and the specific steps are as follows:
  • ⁇ -nicotinamide mononucleotide solution weigh the ⁇ -nicotinamide mononucleotide required by the experimental mice at a ratio of 500 mg/kg body weight, and dissolve it in an appropriate amount of normal saline (each mouse The injection volume is 100 microliters). For example, when preparing the ⁇ -nicotinamide mononucleotide injection required for 10 mice weighing 25 grams, the weighed 125 mg of ⁇ -nicotinamide mononucleotide should be dissolved in 1 ml of normal saline.
  • ⁇ -nicotinamide mononucleotide For the implanted stool plus ⁇ -nicotinamide mononucleotide group constructed in Example 1, 100 microliters were injected into the mouse's abdominal cavity while the experimental mice were implanted in the stool The prepared ⁇ -nicotinamide mononucleotide solution, for the control group of Example 1 plus ⁇ -nicotinamide mononucleotide group, the mice were injected with the same amount of ⁇ -nicotinamide mononucleotide. The control group and the stool implantation group were injected with the same amount of normal saline.
  • mice The heart function of the four groups of mice was measured by ultra-high resolution echocardiography after implantation of feces for 6 hours. After euthanasia, peripheral serum and heart, liver, lung and kidney tissue samples were collected from all mice for analysis of different tissues.
  • FIG. 1 Vehicle represents control mice; Feces represents sepsis In the mouse group, Saline represents normal saline; NMN represents the application of ⁇ -nicotinamide mononucleotide at the onset of sepsis.
  • Fractional Shortening (%) is the short-axis shortening rate, which represents cardiac contractility; MPO represents myeloperoxidase activity; ROS represents the production of reactive oxygen species; MDA represents the content of malondialdehyde.
  • Figure 1 the cardiac contractile function of septic mice was significantly weaker than that of control mice, and ⁇ -nicotinamide mononucleotide improved the cardiac function of septic mice (Figure 1A). Grinding mouse myocardial tissues, using a commercial kit to detect the activity of myeloperoxidase and the production of reactive oxygen species and malondialdehyde in myocardial tissues. The results are shown in Figure 1B-D. Sepsis leads to myocardial tissue marrow.
  • ⁇ -nicotinamide mononucleotide significantly reduced myeloperoxidase activity and reactive oxygen species and malondialdehyde in myocardial tissue of septic mice content. The results show that ⁇ -nicotinamide mononucleotide can improve the heart function of septic mice.
  • FIG. 2 shows the relevant test results of lung tissue.
  • Caspase-3 activity represents the level of apoptosis.
  • the other letters and symbols have the same meaning as in Figure 1.
  • the lung tissue is embedded in formalin, dehydrated and embedded in paraffin. After sectioning, hematoxylin-eosin staining was performed.
  • the representative picture is shown in 2A: the lung tissue of septic mice showed inflammatory reactions such as alveolar wall thickening and cell nucleus aggregation.
  • ⁇ -nicotinamide mononucleotide effectively improved sepsis Inflammatory damage to lung tissue caused by disease.
  • FIG 3 shows the relevant test results of liver tissue.
  • Protein carbonyl represents the content of protein carbonyl group
  • AST represents aspartate aminotransferase that causes liver cell damage
  • other letters and symbols have the same meaning as Figure 1.
  • Protein in liver tissue of septic mice The content of carbonyl and malondialdehyde and the activity of myeloperoxidase were significantly higher than those of control mice, suggesting that the liver tissue of sepsis mice had oxidative stress and inflammatory damage.
  • ⁇ -nicotinamide mono Nucleotides can significantly improve the level of oxidative stress and inflammatory damage in liver tissue caused by sepsis (Figure 3A, B and D).
  • ⁇ -nicotinamide mononucleotide can improve liver tissue lesions in septic mice.
  • FIG 4 shows the related test results of kidney tissue.
  • BUN stands for urea nitrogen that reflects kidney cell damage.
  • Other letters and symbols have the same meaning as Figures 1 and 3.
  • the protein carbonyl and malondialdehyde in the kidney tissue of septic mice The content and the activity of myeloperoxidase were significantly higher than those of control mice, suggesting that oxidative stress and inflammatory damage occurred in the kidney tissue of sepsis mice.
  • ⁇ -nicotinamide mononucleotide can be significantly Improve the level of oxidative stress and inflammatory damage in the kidney tissue caused by sepsis ( Figure 4A, B and D).
  • the increase in serum urea nitrogen content indicates renal insufficiency in septic mice.
  • ⁇ -nicotinamide mononucleotide After the application of ⁇ -nicotinamide mononucleotide, the urea nitrogen content is down-regulated to protect renal function (Figure 4C).
  • ⁇ -nicotinamide mononucleotide can improve renal tissue lesions in septic mice.
  • Example 3 ⁇ -nicotinamide mononucleotide treatment of multiple organ damage in septic mice
  • the administration method of intraperitoneal injection is adopted, and the specific steps are as follows:
  • ⁇ -nicotinamide mononucleotide solution weigh the ⁇ -nicotinamide mononucleotide required by the experimental mice at a ratio of 500 mg/kg body weight, and dissolve it in an appropriate amount of normal saline (each mouse The injection volume is 100 microliters). For example, when preparing the ⁇ -nicotinamide mononucleotide injection required for 10 mice weighing 25 grams, the weighed 125 mg of ⁇ -nicotinamide mononucleotide should be dissolved in 1 ml of physiological saline.
  • mice were injected with 100 into the tail vein Microliters of the prepared ⁇ -nicotinamide mononucleotide solution, for the control group of Example 1 plus ⁇ -nicotinamide mononucleotide group, mice were injected with the same amount of ⁇ -nicotinamide mononucleotide.
  • the control group and the stool implantation group were injected with the same amount of normal saline.
  • mice The heart function of the four groups of mice was measured by ultra-high resolution echocardiography after implantation of feces for 6 hours. After euthanasia, peripheral serum and heart, liver, lung and kidney tissue samples were collected from all mice for analysis of different tissues.
  • mice were anesthetized with 1-2% isoflurane, and the contractile function of the mouse heart was detected by ultra-high resolution echocardiography.
  • the results are shown in Figure 5.
  • NMN-1H represents the application of ⁇ - when sepsis is onset for 1 hour. Nicotinamide mononucleotide, other letters and symbols have the same meaning as above.
  • the cardiac contractile function of sepsis mice was significantly weaker than that of control mice.
  • ⁇ -nicotinamide mononucleotide was used to improve the cardiac function of sepsis mice (Figure 5A).
  • the mouse myocardial tissue was ground, and a commercial kit was used to detect the activity of myeloperoxidase and the production of reactive oxygen species and malondialdehyde in the myocardial tissue.
  • the results are shown in Figure 5B-D.
  • Sepsis leads to myocardial tissue marrow. Increased peroxidase activity and excessive production of reactive oxygen species and malondialdehyde.
  • Application of ⁇ -nicotinamide mononucleotide 1 hour after the onset of sepsis significantly reduced myeloperoxidase activity in myocardial tissue of septic mice And the content of active oxygen and malondialdehyde.
  • the application of ⁇ -nicotinamide mononucleotide one hour after the onset of sepsis can improve the heart function of septic mice.
  • FIG. 6 illustrates the relevant test results of lung tissue.
  • NMN-1H represents the application of ⁇ -nicotinamide mononucleotide at the onset of sepsis one hour, and other letters and symbols have the same meaning as above.
  • Formalin-embedded lung tissues were dehydrated and paraffin-embedded in sections and then stained with hematoxylin and eosin.
  • a representative picture is shown in 6A: The lung tissue of septic mice showed inflammation such as alveolar wall thickening and cell nucleus aggregation.
  • the application of ⁇ -nicotinamide mononucleotide 1 hour after the onset of disease can effectively improve the inflammatory damage of lung tissue caused by sepsis.
  • FIG. 7 shows the results of the related tests of liver tissue.
  • NMN-1H represents the application of ⁇ -nicotinamide mononucleotide at the onset of sepsis one hour, and other letters and symbols have the same meaning as above.
  • FIG 8 illustrates the related test results of kidney tissue.
  • NMN-1H represents the application of ⁇ -nicotinamide mononucleotide at the onset of sepsis one hour, and other letters and symbols have the same meaning as above.
  • the content of protein carbonyl and malondialdehyde and the activity of myeloperoxidase in the kidney tissue of sepsis mice were significantly higher than those of control mice, suggesting that the kidney tissue of sepsis mice had oxidative stress and inflammatory damage
  • the application of ⁇ -nicotinamide mononucleotide 1 hour after the onset of disease can significantly improve the level of oxidative stress and inflammatory damage in the kidney tissue caused by sepsis ( Figure 8A, B and D).
  • ⁇ -nicotinamide mononucleotide was used to down-regulate the urea nitrogen content and protect renal function one hour after the onset of disease ( Figure 8C).
  • ⁇ -nicotinamide mononucleotide can be used to improve renal tissue lesions in septic mice one hour after the onset of sepsis.
  • the present invention proves through preliminary in vivo experiments that the intraperitoneal injection of ⁇ -nicotinamide mononucleotide at the same time or after the preparation of the mouse sepsis model effectively improves the damage of the main organs of the mouse sepsis, and proves that the ⁇ -nicotinamide mononuclear
  • the preventive and therapeutic protective effects of Glycolic acid on multiple organs of septic mice indicate that ⁇ -nicotinamide mononucleotide can be used to prepare drugs for the treatment and prevention of septic organ damage, thereby providing a good basis for diseases in related fields. New treatment methods and approaches.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)

Abstract

La présente invention concerne l'utilisation d'un mononucléotide de β-nicotinamide dans la préparation d'un médicament pour le traitement et/ou la prévention de lésions d'organe induites par une septicémie. La nouvelle utilisation du mononucléotide de β-nicotinamide a un effet thérapeutique et un effet préventif sur les lésions d'organes multiples induites par une septicémie, et le mononucléotide de β-nicotinamide est facilement soluble dans l'eau, est largement répandu et facilement utilisable, et a des voies d'administration diverses.
PCT/CN2020/110120 2019-10-17 2020-08-20 UTILISATION DE β-NMN DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT OU LA PRÉVENTION DE LÉSIONS D'ORGANE INDUITES PAR UNE SEPTICÉMIE WO2021073249A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910988866.0A CN110548040A (zh) 2019-10-17 2019-10-17 β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用
CN201910988866.0 2019-10-17

Publications (1)

Publication Number Publication Date
WO2021073249A1 true WO2021073249A1 (fr) 2021-04-22

Family

ID=68743087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/110120 WO2021073249A1 (fr) 2019-10-17 2020-08-20 UTILISATION DE β-NMN DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT OU LA PRÉVENTION DE LÉSIONS D'ORGANE INDUITES PAR UNE SEPTICÉMIE

Country Status (2)

Country Link
CN (1) CN110548040A (fr)
WO (1) WO2021073249A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110548040A (zh) * 2019-10-17 2019-12-10 苏州大学 β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用
CN114796255A (zh) * 2022-03-30 2022-07-29 深圳市旷逸生物科技有限公司 烟酰胺单核苷酸在保护肝脏免受损伤方面的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014059031A2 (fr) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Biosynthèse et précurseurs de nad pour la prévention et le traitement de l'inflammation
WO2016188091A1 (fr) * 2015-12-11 2016-12-01 邦泰生物工程(深圳)有限公司 Utilisation de nicotinamide mononucléotide pour la préparation d'un médicament indiqué pour prévenir ou lutter contre l'athérosclérose et les maladies cardiovasculaires et cérébrovasculaires, et médicament associé
CN109475572A (zh) * 2016-02-22 2019-03-15 宾夕法尼亚州大学信托人 用于增强肝再生的方法
CN109999052A (zh) * 2018-02-12 2019-07-12 四川大学 β-烟酰胺单核苷酸或其前体在制备治疗或缓解呼吸障碍或疾病的药物或保健品中的用途
CN110548040A (zh) * 2019-10-17 2019-12-10 苏州大学 β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014059031A2 (fr) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Biosynthèse et précurseurs de nad pour la prévention et le traitement de l'inflammation
WO2016188091A1 (fr) * 2015-12-11 2016-12-01 邦泰生物工程(深圳)有限公司 Utilisation de nicotinamide mononucléotide pour la préparation d'un médicament indiqué pour prévenir ou lutter contre l'athérosclérose et les maladies cardiovasculaires et cérébrovasculaires, et médicament associé
CN109475572A (zh) * 2016-02-22 2019-03-15 宾夕法尼亚州大学信托人 用于增强肝再生的方法
CN109999052A (zh) * 2018-02-12 2019-07-12 四川大学 β-烟酰胺单核苷酸或其前体在制备治疗或缓解呼吸障碍或疾病的药物或保健品中的用途
CN110548040A (zh) * 2019-10-17 2019-12-10 苏州大学 β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, XINGCHENG ET AL.: "Role of Oxidative Stress in Organ Dysfunction of Sepsis", CHINESE JOURNAL OF CRITICAL CARE MEDICINE, vol. 39, no. 4, 10 April 2019 (2019-04-10), pages 388 - 392, XP009527353, ISSN: 1002-1949 *

Also Published As

Publication number Publication date
CN110548040A (zh) 2019-12-10

Similar Documents

Publication Publication Date Title
Chen et al. Nrf2 deficiency aggravates Angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6/STAT3-dependent inflammation
CA2458798C (fr) Methode permettant de reduire l'hypertension et l'insuffisance cardiaque
Zhang et al. Protective effect of qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats
WO2021073249A1 (fr) UTILISATION DE β-NMN DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT OU LA PRÉVENTION DE LÉSIONS D'ORGANE INDUITES PAR UNE SEPTICÉMIE
Wang et al. FTZ ameliorates diabetic cardiomyopathy by inhibiting inflammation and cardiac fibrosis in the streptozotocin-induced model
CA2210351C (fr) Methode de traitement des maladies vasculaires evolutives chroniques
Zhao et al. Kudzu celery decoction exerts protection against sepsis‐induced myocardial injury
Wang et al. Curcumin analog JM-2 alleviates diabetic cardiomyopathy inflammation and remodeling by inhibiting the NF-κB pathway
Shakour et al. Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Bao et al. Artemisinin and its derivate alleviate pulmonary hypertension and vasoconstriction in rodent models
Xiao et al. Sanggenon C protects against pressure overload‑induced cardiac hypertrophy via the calcineurin/NFAT2 pathway
KR20010006511A (ko) 만성 진행성 혈관 손상 질환의 치료방법
Shi et al. MiR-208a participates with sevoflurane post-conditioning in protecting neonatal rat cardiomyocytes with simulated ischemia-reperfusion injury via PI3K/AKT signaling pathway.
CN101732323B (zh) 低剂量熊果酸制备治疗糖尿病早期肾脏病变药物的用途
CN111481535B (zh) Idhp用于制备抗败血症及其诱发的心肌损伤药物的应用
Zhao et al. Effect of Shenfu injection on porcine renal function after cardiopulmonary resuscitation
Tian et al. Adiponectin improves the therapeutic efficacy of mesenchymal stem cells by enhancing their engraftment and survival in the peri-infarct myocardium through the AMPK pathway
Rutledge et al. Liraglutide protects against diastolic dysfunction and improves ventricular protein translation
Tai et al. CREG improves cardiac function by regulating cardiomyocytes’ autophagy in diabetic myocardial infarction rats.
CN114984226B (zh) 苹果酸酶1在制备防治肺动脉高压的药物中的应用
CN108379585A (zh) Hdac4抑制剂在制备治疗心力衰竭的药物中的应用
Shi et al. [Retracted] Insulin Aspart Combined with Exercise Therapy in Spleen Deficiency Type Gestational Diabetes Mellitus: The Effect on Disease Control and Pregnancy Outcomes
CN116509874A (zh) 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
WO2021093376A1 (fr) Utilisation d'un inhibiteur de phosphodiestérase 5 dans la préparation d'un médicament permettant de résister à des maladies fibrotiques
Kolieb et al. Effect of Xanthenone Versus Irisin in Alleviating Renal Ischemic Reperfusion Injury through Modifying the PI3K/AKT/eNOS and TLR-4/NFkB Pathways

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20877485

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20877485

Country of ref document: EP

Kind code of ref document: A1